Floatz logo

Raloxifene

Prostate Adenocarcinoma

Mayo ClinicSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

97 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB

View all 50 →

Same molecule, other indications

Raloxifene is also rated in:

schizophreniform disorderDormant
A
Indicative ·
83 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →